semaglutide trial adolescents obesity 2022 Frontiers semaglutide adolescent obesity trial 2022

NCD Risk Factor Collaboration (NCD-RisC) Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults

Amycretin, Novo Nordisks oral dual GLP-1/amylin agonist, showed 13% weight loss in early trials, signaling a move toward multi-pathway oral therapies

GLP-1 drugs can help, but lasting results require a plan beyond the prescription

Pair with a balanced diet

These fall under a different regulatory category, and their safety and quality controls vary dramatically

These reductions are part of broader efforts to expand access , improve insurance coverage , and reduce out-of-pocket costs for patients who need these medications for diabetes or obesity-related health risks